Literature DB >> 2442551

The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension.

K Bolzano, J Arriaga, R Bernal, H Bernardes, J L Calderon, J Debruyn, F Dienstl, J Drayer, T L Goodfriend, W Gross.   

Abstract

In a multicenter, parallel, double-blind study, lisinopril was compared with atenolol in the treatment of mild to moderate essential hypertension. Four hundred ninety patients were randomized to a once-a-day treatment with lisinopril 20 mg or atenolol 50 mg for 4 weeks, and the doses of lisinopril or atenolol were increased up to 80 mg or 200 mg, respectively, at 4-week intervals if sitting diastolic blood pressure (SDBP) was not well controlled. Hydrochlorothiazide (HCTZ) 12.5 or 25 mg was added after 12 weeks, if necessary, and titrated upward after 4 weeks to a maximum dose of 25 or 50 mg/day. Lisinopril and atenolol reduced SDBP to a similar extent. All reductions from baseline in sitting diastolic and systolic blood pressure were significant (less than 0.01). Lisinopril produced a significant (less than 0.01) greater reduction in sitting systolic blood pressure (SSBP) than atenolol. Addition of HCTZ caused further blood pressure reductions (p less than 0.01). Five patients (1.7%) on lisinopril and four (2.0%) on atenolol developed skin rashes during weeks 1-12. Two patients (0.7%) on lisinopril 80 mg developed proteinuria (greater than 1 g/day). Cough occurred more often with lisinopril (4.5%), and elevated triglycerides occurred more often with atenolol (2.0%).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442551     DOI: 10.1097/00005344-198700003-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.

Authors:  O Samuelsson; T Hedner; S Ljungman; H Herlitz; B Widgren; K Pennert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

5.  Lisinopril: dose-peak effect relationship in essential hypertension.

Authors:  V J Cirillo; H J Gomez; J Salonen; R Salonen; V Rissanen; J A Bolognese; R Nyberg; K Kristianson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

Review 6.  Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  S G Lancaster; P A Todd
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 7.  Treatment of hypertension based on both systolic and diastolic pressure could influence the cost of therapy.

Authors:  M Safar
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

Review 8.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

9.  Lisinopril versus atenolol: decrease in systolic versus diastolic blood pressure with converting enzyme inhibition.

Authors:  B E Pannier; V G Garabedian; O Madonna; M Fouchard; B Darne; M E Safar
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

10.  Antihypertensive Effect and Tolerability of Perindopril in Indian Hypertensive and Type 2 Diabetic Patients: 1-Year Randomised, Double-Blind, Parallel Study vs Atenolol.

Authors:  Y K Seedat; I G Randeree
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.